428 related articles for article (PubMed ID: 24315802)
1. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period.
Schiller B; Bhat P; Sharma A
Clin Ther; 2014 Jan; 36(1):70-83. PubMed ID: 24315802
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min.
Auerbach M; Strauss W; Auerbach S; Rineer S; Bahrain H
Am J Hematol; 2013 Nov; 88(11):944-7. PubMed ID: 23828252
[TBL] [Abstract][Full Text] [Related]
3. Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease.
Schwenk MH
Pharmacotherapy; 2010 Jan; 30(1):70-9. PubMed ID: 20030475
[TBL] [Abstract][Full Text] [Related]
4. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease.
Lu M; Cohen MH; Rieves D; Pazdur R
Am J Hematol; 2010 May; 85(5):315-9. PubMed ID: 20201089
[TBL] [Abstract][Full Text] [Related]
5. Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial
.
Macdougall IC; Strauss WE; Dahl NV; Bernard K; Li Z
Clin Nephrol; 2019 Apr; 91(4):237-245. PubMed ID: 30802204
[TBL] [Abstract][Full Text] [Related]
6. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.
Macdougall IC; Strauss WE; McLaughlin J; Li Z; Dellanna F; Hertel J
Clin J Am Soc Nephrol; 2014 Apr; 9(4):705-12. PubMed ID: 24458078
[TBL] [Abstract][Full Text] [Related]
7. Iron indices and intravenous ferumoxytol: time to steady-state.
Kapoian T; O'Mara NB; Carreon M; Gajary A; Rizkala A; Lefavour G; Sherman RA; Walker J
Ann Pharmacother; 2012 Oct; 46(10):1308-14. PubMed ID: 22968523
[TBL] [Abstract][Full Text] [Related]
8. The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale.
Macdougall IC; Dahl NV; Bernard K; Li Z; Batycky A; Strauss WE
BMC Nephrol; 2017 Apr; 18(1):117. PubMed ID: 28372549
[TBL] [Abstract][Full Text] [Related]
9. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
10. Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney disease.
Coyne DW
Expert Opin Pharmacother; 2009 Oct; 10(15):2563-8. PubMed ID: 19708851
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial.
Goldstein SL; Morris D; Warady BA
Am J Kidney Dis; 2013 Apr; 61(4):588-97. PubMed ID: 23245582
[TBL] [Abstract][Full Text] [Related]
12. Safety of ferumoxytol in patients with anemia and CKD.
Singh A; Patel T; Hertel J; Bernardo M; Kausz A; Brenner L
Am J Kidney Dis; 2008 Nov; 52(5):907-15. PubMed ID: 18824288
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
Geisser P; Rumyantsev V
Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
[TBL] [Abstract][Full Text] [Related]
14. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.
Provenzano R; Schiller B; Rao M; Coyne D; Brenner L; Pereira BJ
Clin J Am Soc Nephrol; 2009 Feb; 4(2):386-93. PubMed ID: 19176796
[TBL] [Abstract][Full Text] [Related]
15. Safety of total dose iron dextran infusion in geriatric patients with chronic kidney disease and iron deficiency anemia.
Dossabhoy NR; Turley S; Gascoyne R; Tapolyai M; Sulaiman K
Ren Fail; 2014 Aug; 36(7):1033-7. PubMed ID: 24845687
[TBL] [Abstract][Full Text] [Related]
16. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.
McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ
Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312
[TBL] [Abstract][Full Text] [Related]
17. Use of intravenous iron supplementation in chronic kidney disease: an update.
Macdougall IC; Geisser P
Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
Bailie GR
Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
[TBL] [Abstract][Full Text] [Related]
19. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB
Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534
[TBL] [Abstract][Full Text] [Related]
20. Ferumoxytol infusion in pediatric patients with gastrointestinal disorders: first case series.
Hassan N; Cahill J; Rajasekaran S; Kovey K
Ann Pharmacother; 2011 Dec; 45(12):e63. PubMed ID: 22116997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
